This English version is intended to be a reference material for the convenience of users. In the event of inconsistency between the Japanese original and this English translation, the former shall prevail.

Summary of investigation results

Natalizumab (genetical recombination)

September 13, 2016

Non-proprietary name

Natalizumab (genetical recombination)

Brand name (Marketing authorization holder)

Tysabri for I.V. Infusion 300 mg (Biogen Japan Ltd)

Indications

The prevention of relapse and delaying the accumulation of physical disability in multiple sclerosis

Summary of revision

1. Progressive multifocal leukoencephalopathy (PML)

   Precautions for patients with a high risk of PML should be added in the Important Precautions section.

2. Granule cell neuronopathy

   “Granule cell neuronopathy” should be added in the “Progressive multifocal leukoencephalopathy” subsection of the Clinically significant adverse reaction section.

3. Acute retinal necrosis

   Precautions for acute retinal necrosis should be newly added in the Important Precautions section. “Acute retinal necrosis” should be newly added in the Clinically significant adverse reaction section.

Background of the revision and investigation results

1. The company core datasheet (CCDS)* has been updated. In addition, the European Medicines Agency (EMA) has taken new action to alert caution for the risk of PML. Following an investigation result based on the opinions of expert advisors and the

Pharmaceuticals and Medical Devices Agency
Office of Safety I
3-3-2 Kasumigaseki, Chiyoda-ku, Tokyo 100-0013 Japan
E-mail: safety.info@pmda.go.jp

available evidence, the MHLW/PMDA concluded that revision of the package insert was necessary.

2. Cases of granule cell neuronopathy have been reported overseas and the CCDS* has been updated. Following an investigation result based on the opinions of expert advisors and the available evidence, the MHLW/PMDA concluded that revision of the package insert was necessary.
3. Cases of acute retinal necrosis have been reported overseas and the CCDS* has been updated. In addition, the EMA has taken new action to alert caution for the risk of acute retinal necrosis. Following an investigation result based on the opinions of expert advisors and the available evidence, the MHLW/PMDA concluded that revision of the package insert was necessary.

The number of reported adverse reactions and fatal cases in the last 3 fiscal years in Japan

1. N/A
2. No case associated with granule cell neuronopathy has been reported.
3. No case associated with acute retinal necrosis has been reported.

Note:
*CCDS is prepared by the marketing authorization holder and covers materials relating to safety, indications, dosing, pharmacology, and other information concerning the product.

Pharmaceuticals and Medical Devices Agency
Office of Safety I
3-3-2 Kasumigaseki, Chiyoda-ku, Tokyo 100-0013 Japan
E-mail: safety.info@pmda.go.jp